Takeda Pharmaceutical's Hyqvia Approved in Japan for Patients With Immune Disorders

MT Newswires Live2024-12-27

Takeda Pharmaceutical (TAK) said Friday that the Japanese Ministry of Health, Labor and Welfare has approved the use of Hyqvia in patients with agammaglobulinemia or hypogammaglobulinemia.

The two rare disorders are characterized by low levels or the absence of antibodies and an increased risk of serious infections caused by primary or secondary immunodeficiency, the company said.

Hyqvia is a plasma-derived therapy for subcutaneous injection that combines one vial of immunoglobulin 10% and one vial of recombinant human hyaluronidase, the company said.

The approval was based on results from two 16-patient phase 3 studies in Japan and two phase 3 clinical trials in North America.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2494876099?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-27 16:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494876099","market":"us","top_or_hot":-1,"title":"Takeda Pharmaceutical's Hyqvia Approved in Japan for Patients With Immune Disorders","media":"MT Newswires Live","content":"<html><body><p> Takeda Pharmaceutical (TAK) said Friday that the Japanese Ministry of Health, Labor and Welfare has approved the use of Hyqvia in patients with agammaglobulinemia or hypogammaglobulinemia.</p><p>The two rare disorders are characterized by low levels or the absence of antibodies and an increased risk of serious infections caused by primary or secondary immunodeficiency, the company said.</p><p>Hyqvia is a plasma-derived therapy for subcutaneous injection that combines one vial of immunoglobulin 10% and one vial of recombinant human hyaluronidase, the company said.</p><p>The approval was based on results from two 16-patient phase 3 studies in Japan and two phase 3 clinical trials in North America.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Pharmaceutical's Hyqvia Approved in Japan for Patients With Immune Disorders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Pharmaceutical's Hyqvia Approved in Japan for Patients With Immune Disorders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-27 16:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Takeda Pharmaceutical (TAK) said Friday that the Japanese Ministry of Health, Labor and Welfare has approved the use of Hyqvia in patients with agammaglobulinemia or hypogammaglobulinemia.The two rare...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2494876099","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494876099","pubTimestamp":1735288778,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Takeda Pharmaceutical (TAK) said Friday that the Japanese Ministry of Health, Labor and Welfare has approved the use of Hyqvia in patients with agammaglobulinemia or hypogammaglobulinemia.The two rare","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药","BK4007":"制药"},"translate_title":"武田制药Hyqvia在日本获批用于免疫紊乱患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":0.9},"content_text":"Takeda Pharmaceutical (TAK) said Friday that the Japanese Ministry of Health, Labor and Welfare has approved the use of Hyqvia in patients with agammaglobulinemia or hypogammaglobulinemia.The two rare disorders are characterized by low levels or the absence of antibodies and an increased risk of serious infections caused by primary or secondary immunodeficiency, the company said.Hyqvia is a plasma-derived therapy for subcutaneous injection that combines one vial of immunoglobulin 10% and one vial of recombinant human hyaluronidase, the company said.The approval was based on results from two 16-patient phase 3 studies in Japan and two phase 3 clinical trials in North America.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2494876099"}